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A total of 207 Staphylococcus aureus strains, including 105 well-characterized strains with decreased sus-
ceptibility to vancomycin (17 vancomycin-intermediate S. aureus [VISA] and 88 heteroresistant VISA [hVISA]
strains) and 102 wild-type methicillin-resistant S. aureus (MRSA-WT) strains were tested by reference/
standardized broth microdilution and disk diffusion methods, as well as by Etest (AB BIODISK, Solna,
Sweden), against daptomycin and vancomycin. The lowest concentration of antimicrobial agent that killed
>99.9% of the initial inoculum was defined as the minimum bactericidal concentration (MBC) endpoint, and
time-kill curves were performed in selected strains to further evaluate bactericidal activity. All MRSA-WT and
hVISA strains were inhibited by <1 g/ml of daptomycin, while the VISA strains showed slightly higher
daptomycin MICs (range, 0.5 to 4 g/ml). All daptomycin MBC results were at the MIC or twofold higher. In
contrast, 14.7% of MRSA-WT, 69.3% of hVISA, and all VISA strains showed a vancomycin MBC/MIC ratio of
>32 or an MBC of >16 g/ml (tolerant). The correlation coefficients between broth microdilution and disk
diffusion method results were low for daptomycin (0.07) and vancomycin (0.11). Eight (3.8%) strains (all hVISA
or VISA) were “nonsusceptible” to daptomycin by broth microdilution methods but susceptible by the disk
diffusion method. For vancomycin, 35 (16.9%) strains were nonsusceptible by broth microdilution methods but
susceptible by disk diffusion methods. In conclusion, daptomycin was highly bactericidal against S. aureus
strains, and its bactericidal activity was not affected by decreased susceptibility to vancomycin. In contrast,
many (one in seven) contemporary MRSA-WT, the majority of hVISA, and all VISA strains showed vancomycin
MBC/MIC ratios consistent with tolerance, a predictor of poor clinical response. Disk diffusion tests generally
failed to detect strains categorized as nonsusceptible to daptomycin or vancomycin by the reference broth
microdilution method or Etest, and reassessment of breakpoints should be immediately attempted for MIC
methods suggested as the test of choice.
The superiority of bactericidal over bacteriostatic antimicro-
bials is very controversial and may not translate to better clin-
ical outcome for the majority of infections. However, there are
a few studies suggesting that a bactericidal agent would be
preferable in some clinical situations, such as endocarditis,
meningitis, osteomyelitis, and systemic infections in immuno-
compromised patients (1, 13, 19). In endocarditis, for example,
bacteria within cardiac valvular vegetations may reach very
high concentrations (108 to 1010 organisms per gram of tissue),
and at such densities, rates of metabolism and cell division
appear to be reduced, resulting in decreased susceptibility to
the bactericidal effects of cell wall-active agents. The bacteria
are somewhat dormant, being surrounded by fibrin, platelets,
and possibly calcified material. Bacteria that could be consid-
ered susceptible to various antimicrobials in most clinical sit-
uations are relatively resistant in endocarditis. Clinical cure
can often be achieved, but prolonged administration of rela-
tively high doses of a bactericidal, cell wall-active antibacterial
agent is generally required for true sterilization of the vegeta-
tion to kill any dormant bacteria (1, 24). However, the clinical
importance of bactericidal activity in the treatment of infec-
tious endocarditis is very difficult to evaluate due to the high
mortality rates of the disease (11, 15, 27).
Daptomycin is a cyclic lipopeptide which has been re-
cently approved by the U.S. Food and Drug Administration
for the treatment of complicated skin and skin structure
infections and has been evaluated for the treatment of sev-
eral other infections, including successful studies of bacte-
remia and infectious endocarditis (14, 21, 26). Daptomycin
has a unique mechanism of action with no cross-resistance
to glycopeptide (teicoplanin and vancomycin)-resistant
strains. This lipopeptide antimicrobial acts on the cytoplas-
mic membrane in the presence of physiological levels of
calcium ions, and its in vitro susceptibility testing requires
appropriate supplementation of the test media with calcium
(50 g/liter in Mueller-Hinton broth) (12).
Vancomycin, the first glycopeptide antimicrobial agent, has
been used clinically for nearly 5 decades, and susceptibility
testing results document continued in vitro activity against a
wide variety of gram-positive species. However, more recently,
the emergence of vancomycin-intermediate (VISA) and -resis-
tant Staphylococcus aureus has called into question the efficacy
of this antimicrobial in the treatment of some serious staphy-
lococcal infections (3, 8, 10, 18, 25, 28). Also, there have been
several studies demonstrating that vancomycin bactericidal ac-
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tivity is significantly reduced during the bacterial stationary
phase, under anaerobic conditions, and at an increased inoc-
ulum (1, 11, 20), even when vancomycin MICs are in the
susceptible range.
We evaluated the bactericidal activities of daptomycin and van-
comycin against a very large contemporary collection of VISA
and heteroresistant VISA (hVISA) strains compared to a collec-
tion of wild-type methicillin-resistant S. aureus (MRSA-WT)
strains. We also evaluated the correlation between the suscepti-
bility testing results generated by reference broth microdilution
(6), disk diffusion (7), and Etest (AB BIODISK, Solna, Sweden)
for these two antimicrobials.
MATERIALS AND METHODS
Organism collection. A collection of 207 S. aureus strains was selected for the
study. The collection was composed of two groups of strains.
(i) hVISA/VISA group. The hVISA/VISA group consisted of 105 isolates. The
hVISA subset included 88 isolates with vancomycin MIC results of 4 g/ml by
the reference broth microdilution method that showed a subpopulation with a
vancomycin MIC at 4 g/ml when tested with a high inoculum (a heteroge-
neous population). This collection has been well characterized by Wootton et al.
(29) and Howe et al. (17). The VISA subset included 17 isolates with vancomycin
MIC results of 8 g/ml and a homogeneous population. Ten strains were defined
by Wooton et al. (29), and seven strains were provided by the Network on
Antimicrobial Resistance in S. aureus (http://www.narsa.net).
(ii) MRSA-WT group. The MRSA-WT group consisted of 102 oxacillin-resis-
tant S. aureus strains with a homogeneous population of vancomycin MIC results
at 2 g/ml (wild type). These isolates were collected from more than 50
medical centers worldwide in 2003. No more than two strains per medical center
were included.
Eighteen strains, selected from the MRSA-WT group based on the vancomy-
cin minimum bactericidal concentration (MBC) results, were further evaluated
by time-kill curve experiments. This collection included 15 MRSA-WT clinical
strains that demonstrated elevated MBC/MIC ratios (tolerance) for vancomycin
and 3 MRSA-WT clinical strains with a vancomycin MBC equal to the MIC at
the same value. In addition, three S. aureus ATCC strains (29213, 43300, and
33591) were included in the time-kill curve experiments.
Susceptibility testing. MICs were determined by broth microdilution for dap-
tomycin, vancomycin, and oxacillin with appropriate medium variations (50 mg/
liter of calcium) for testing daptomycin (6, 12). The log2 dilution ranges tested
were as follows: daptomycin, 128 to 0.12 g/ml; oxacillin, 4 to 1 g/ml; and
vancomycin 32 to 1 g/ml.
MBCs for daptomycin and vancomycin were assessed by plating the entire
volume of broth (100 l) from the broth microdilution MIC well and from the
log2 dilutions above the MIC for each organism onto agar growth media.
Quantitative colony counts were performed on the starting inoculum at the
time the MIC test was performed. The lowest concentration of antimicrobial
agent that killed 99.9% of the starting inoculum was defined as the MBC
endpoint (22, 23). Tolerance was defined as an MBC/MIC ratio of 32, and
isolates with an MBC/MIC ratio of 16 associated with an MBC of 16 g/ml,
the proposed CLSI resistant breakpoint for vancomycin (6), were also con-
sidered tolerant (20).
Disk diffusion tests with 30-g daptomycin and vancomycin disks were
performed on all 207 isolates according to the method published by the CLSI
for 100-mm Mueller-Hinton agar plates (7). All isolates were also suscepti-
bility tested against daptomycin and vancomycin by Etest, according to the
manufacturer’s recommendations. In addition, all MRSA-WT strains with
vancomycin MBC/MIC ratios consistent with tolerance (15 strains; MBC/
MIC ratio  32 and/or MBC  16 g/ml) were evaluated by the Etest
methodology on brain-heart infusion agar against vancomycin and teicopla-
nin using two inocula (0.5 and 2 McFarland standards). This technique was
used to detect hVISA strains, and the criteria used to characterize hVISA
were as follows: MICs  8 g/ml for both vancomycin and teicoplanin after
48 h of incubation at 37°C (29).
The quality control strains, S. aureus ATCC 25923 and Enterococcus faecalis
ATCC 29212, were tested along with every set of tests.




No. of isolates (cumulative %) at MIC/MBC (g/ml) of:





2 (2.0) 41 (42.2) 56b (97.1) 3 (100.0) 0 0 0 0 0
hVISA (88) 0 2 (2.3) 52 (61.4) 34 (100.0) 0 0 0 0 0




c  9 (8.8) 82 (89.2) 11 (100.0) 0 0 0 0
hVISA (88)   0 (0.0) 9 (10.2) 61 (79.5) 18 (100.0) 0 0 0





0 29 (28.4) 65 (92.2) 7 (99.0) 1 (100.0) 0 0 0 0
hVISA (88) 0 2 (2.3) 35 (40.9) 49 (97.7) 2 (100.0) 0 0 0 0




  2 (2.0) 38 (39.2) 23 (61.8) 9 (70.6) 15 (85.3) 4 (89.2) 11 (100.0)
hVISA (88)   0 3 (3.4) 9 (14.9) 5 (19.3) 3 (22.7) 7 (30.7) 61 (100.0)
VISA (17)   0 0 0 0 0 0 17 (100.0)
a Clinical MRSA isolate with vancomycin MIC of 2 g/ml (homogeneous populations) collected from medical centers worldwide in 2003.
b The underlined numbers are modal values.
c —, dilution not tested.
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Time-kill curve experiments. Time-kill bactericidal activities were determined
for daptomycin and vancomycin (22, 23). Vancomycin was tested at 2, 4, and
8 MIC, with colonies counted at time zero (T0), T4, T8, T24, and T48, while
daptomycin was tested at 2, 4, and 8 MIC with colony counts performed at
T0, T4, T8, and T24. Bactericidal activity was defined as 3 log10 reduction in the
initial inoculum within 24 h of incubation (22).
RESULTS
Table 1 summarizes the MIC and MBC results for dapto-
mycin and vancomycin. The strains were grouped according to
the type of pattern of susceptibility to vancomycin as (i)
MRSA-WT strains, (ii) hVISA strains, and (iii) VISA strains.
All MRSA-WT and hVISA strains were inhibited by 1 g/ml
of daptomycin. A slight skewing toward a higher daptomycin
MIC result was noted when the hVISA (MIC50, 0.5 g/ml;
MIC90, 1 g/ml) and VISA (MIC50, 1 g/ml; MIC90, 2 g/ml)
strains were compared to the MRSA-WT group (MIC50 and
MIC90, 0.5 g/ml). The highest daptomycin MBC result ob-
served was 4 g/ml (three isolates, all VISA), and 93.2% of the
isolates showed a daptomycin MBC of 1 g/ml (Table 1).
Eight of 11 daptomycin MBC results of 2 g/ml and all three
MBC results of 4 g/ml were observed among the VISA
strains.
Only 61.8% of the MRSA-WT isolates showed vancomycin
MBC results of 2 g/ml, the proposed CLSI (6) vancomycin-
susceptible MIC breakpoint (Table 1). Furthermore, 14.9% of
the hVISA and none of the VISA strains showed vancomycin
MBC results of 2 g/ml. The number of occurrences (per-
centage) of isolates with vancomycin MBC results of 16
g/ml (the CLSI resistant breakpoint) (6) were 15 (14.7%), 68
(77.3%), and 17 (100.0%) among the MRSA-WT, hVISA, and
VISA groups, respectively (Table 1).
All daptomycin MBC results were at the MIC or only two-
fold higher than the MIC, and the MBC/MIC ratio results were
not significantly affected by susceptibility to vancomycin (Table 2).
All three groups of S. aureus (MRSA-WT, hVISA, and VISA)
showed very similar MBC/MIC ratio results for daptomycin.
Conversely, 14.7% of MRSA-WT strains, 69.3% of hVISA
strains, and all VISA strains showed vancomycin MBC/MIC
ratios consistent with a definition of tolerance (MBC/MIC 
32 and/or MBC  16 g/ml).
All MRSA-WT strains with vancomycin MBC/MIC ratios
consistent with tolerance (15 strains) showed an increase in the
vancomycin and teicoplanin MIC results when tested by the
Etest method using the high inoculum (data not shown). How-
ever; according to the criteria proposed by Wootton et al. (29),
only one strain was considered hVISA (strain 16546A; MICs of
8 g/ml for both vancomycin and teicoplanin after 48 h of
incubation).
The time-kill curve results for vancomycin and daptomy-
cin are summarized in Table 3. Since both antimicrobials
demonstrated time-dependent killing, the concentration of
the drug (2, 4, and 8 MIC) had little effect on the
killing activity, and Table 3 presents average colony count
values for 2, 4, and 8 MIC in log10 CFU/ml. Dapto-
mycin generally showed potent and rapid bactericidal activ-
ity (Table 3 and Fig. 1, top). Bactericidal action by dapto-
mycin was achieved after 4 h of incubation for 16 of 21
strains tested (76.2%), including 12 of the 15 clinical strains
(80.0%) with high vancomycin MBC/MIC ratios. A 3 log10
TABLE 2. Distribution of isolates according to MBC/MIC










1 80 (78.4) 69 (78.4) 12 (70.6) 42 (41.2) 11 (12.5)
2 22 (21.6) 19 (21.6) 5 (29.4) 19 (18.6) 5 (5.7)
4 12 (11.8) 4 (4.5)
8 14 (13.7) 7 (8.0)
16 15 (14.7)a 61 (69.3)a 17 (100.0)a
a All isolates had vancomycin MBCs of 16 g/ml.
TABLE 3. Time-kill curve results for vancomycin and daptomycin
tested against bacteremic MRSA strains
Isolate Antimicrobialagent
Reduction in log10




170A Vancomycin 0.9 1.7 2.0 2.8 Static
Daptomycin 4.8 5.6 6.3 c  d Cidal
100A Vancomycin 0.5 1.1 1.9 2.1 Static
Daptomycin 6.1 c 6.1 c 6.1 c  Cidal e
13851A Vancomycin 0.7 1.1 2.9 4.3 Static e
Daptomycin 4.8 6.1 c 6.1 c  Cidal
16546A Vancomycin 0.3 0.8 2.6 3.6 Static f
Daptomycin 3.5 4.8 5.7 c  Cidal g
14382A Vancomycin 0.1 0.4 1.7 3.0 Static
Daptomycin 2.7 4.4 5.6 c 5.6 c Cidal
2345A Vancomycin 0.5 1.0 2.4 3.4 Static e
Daptomycin 4.0 6.0 c 6.0 c 6.0 c Cidal
2308A Vancomycin 0.8 1.3 3.0 4.1 Cidal
Daptomycin 4.2 6.0 c 6.0 c  Cidal
1416A Vancomycin 0.1 0.8 2.8 3.9 Static e
Daptomycin 3.4 4.8 5.9 c  Cidal
2336A Vancomycin 0.4 0.9 3.2 5.6 c Cidal
Daptomycin 3.2 5.8 c 5.8 c  Cidal
16542A Vancomycin 0.3 1.0 3.8 5.5 c Cidal
Daptomycin 3.2 4.1 5.5 c  Cidal
16160A Vancomycin 0.5 1.7 3.6 4.2 Cidal
Daptomycin 2.2 2.6 3.8 6.0 c Cidal
5642A Vancomycin 0.5 0.7 2.4 3.7 Static e
Daptomycin 2.6 4.0 4.3  Cidal g
561A Vancomycin 0.3 0.8 2.0 3.6 Static e
Daptomycin 3.6 5.7 c 5.7 c  Cidal
16325A Vancomycin (0.1) h 0.3 2.3 3.2 Static e
Daptomycin 3.8 6.0 c 6.0 c  Cidal
456A Vancomycin 0.5 1.3 3.6 3.9 Cidal
Daptomycin 4.5 5.6 c 5.6 c  Cidal
424A Vancomycin 0.4 1.0 3.5 3.5 Cidal
Daptomycin 3.1 5.7 c 4.8  Cidal
3811A Vancomycin 1.0 1.6 2.8 3.9 Static e
Daptomycin 2.8 3.7 4.9  Cidal
14854A Vancomycin 0.8 1.2 3.0 4.2 Cidal
Daptomycin 4.4 5.2 6.0 c  Cidal
ATCC 29213 Vancomycin 1.2 1.4 2.7 4.6 Static e
Daptomycin 3.2 5.9 c 5.9 c 5.9 c Cidal
ATCC 43300 Vancomycin 0.7 1.0 2.8 3.7 Static f
Daptomycin 2.3 2.9 4.0  Cidal g
ATCC 33591 Vancomycin 0.5 1.3 3.8 4.5 Cidal
Daptomycin 4.0 4.8 5.7 c  Cidal
a Compared to the initial inoculum. The values represent averages of 2, 4,
and 8 reductions in log10 CFU/ml.
b Bactericidal (Cidal) activity was defined as 3 log10 reduction in the initial
inoculum within 24 h of incubation.
c No bacterial growth was detected.
d , incubated for 24 h only.
e Bactericidal activity was achieved only at 48 h of incubation.
f Bactericidal activity was achieved at 24 h when tested at 4 and/or 8 MIC.
g Bacteriostatic activity when tested at 2 MIC.
h Value in parentheses represents the increase in the log10 CFU/ml.
2332 SADER ET AL. ANTIMICROB. AGENTS CHEMOTHER.
reduction in the initial inoculum was observed with 20
strains (95%) after 8 h of incubation and with all strains
after 24 h of incubation. In contrast, vancomycin exhibited
only modest and slow killing (Table 3 and Fig. 1, bottom).
The reduction in CFU/ml was generally 1 log10 unit after 8 h
of incubation and 3 log10 units after 24 h of incubation.
Among the 15 MRSA-WT strains that exhibited vancomycin
MBC/MIC ratios consistent with tolerance, vancomycin
showed bacteriostatic effects in only 9 strains (60.0%).
A scattergram illustrating the correlation between the
broth microdilution MIC and the disk diffusion zone diam-
eter results for daptomycin is shown in Fig. 2. Eight strains
were considered nonsusceptible to daptomycin (MIC  2
g/ml) when tested by the broth microdilution method but
susceptible when tested by the disk diffusion method using
the current CLSI (7) interpretation criteria. All eight strains
were in the hVISA/VISA groups. The correlation coefficient
was only 0.01.
A scattergram showing the correlation between the broth
microdilution MIC and the disk diffusion zone diameter
results for vancomycin is shown in Fig. 3. Thirty-five strains
(17 VISA and 18 hVISA) had intermediate vancomycin
MICs (4 to 8 g/ml) as categorized by the proposed new
CLSI breakpoints (6). However, these isolates had inhibi-
tion zone diameters of 16 mm and were considered sus-
ceptible according to CLSI breakpoints for the disk diffusion
test (15 mm) (6, 7). The inhibitory-zone diameter varied
from 16 to 19 mm among the seven VISA strains with broth
FIG. 1. Time-kill curve results for strain 170A tested against dap-
tomycin (top) and vancomycin (bottom).
FIG. 2. Scattergram showing the correlation between the daptomycin broth microdilution MIC and disk zone diameter results.
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FIG. 3. Scattergram showing the correlation between the vancomycin broth microdilution MIC and disk zone diameter results.
FIG. 4. Scattergram showing the correlation between the daptomycin broth microdilution and Etest MIC results.
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microdilution MICs of 8 g/ml. The correlation coefficient-
was also very low (0.09).
The Etest results correlated well with broth microdilution
MIC results for daptomycin (Fig. 4), with a slight tendency
toward lower Etest MICs. There was nearly complete categor-
ical agreement between the two methods when MRSA-WT
strains were tested, and the rates of major and very major
errors for the Etest method were 1.9% (2 of 102) when
hVISA/VISA strains were tested (1.0% overall). However, if
the number of resistant strains had been used as the denom-
inator, the very major error rate for the Etest would have
been 25% (2 of 8).
DISCUSSION
For the treatment of high-bacterial-density infections, such
as bacterial endocarditis and serious infections in immunocom-
promised patients, bactericidal activity is preferred (9, 11, 19,
26). The results of the present study endorse previous experi-
ences that showed a more rapid and potent bactericidal activity
for daptomycin than for vancomycin (2, 4, 5, 13). In addition,
we demonstrated that daptomycin remained highly active (bac-
tericidal) against S. aureus strains with reduced susceptibility to
vancomycin (VISA and hVISA strains).
Our results also indicate that the disk diffusion method
fails to detect resistance to either vancomycin or daptomycin
as currently defined by the CLSI documents (6, 7). The fact
that the disk diffusion method does not differentiate strains
with reduced susceptibility to vancomycin (MIC, 4 to 8 g/
ml) from susceptible strains (MIC  2 g/ml) is well known
(6, 7, 16). However, the CLSI still provides vancomycin disk
diffusion breakpoints for staphylococci (6, 7). Regarding
daptomycin, the disk has been removed from the market and
the disk diffusion breakpoints were correctly withdrawn
from CLSI documents until the method can be adjusted for
appropriate detection of daptomycin-nonsusceptible strains
(7). Etest results showed excellent correlation with broth
microdilution MIC results for testing daptomycin and rep-
resent a reasonable option for susceptibility testing with this
antimicrobial agent by an agar diffusion technique. How-
ever, the ability of the Etest to detect isolates with decreased
susceptibility to daptomycin could not be evaluated prop-
erly, since only eight daptomycin-nonsusceptible strains
could be included in the study.
In summary, daptomycin was highly bactericidal against es-
sentially all S. aureus strains, and its bactericidal activity was
not affected by decreased susceptibility to vancomycin. In con-
trast, the majority of hVISA strains (69.3%), all VISA strains,
and a significant percentage of MRSA-WT strains (14.7%)
showed vancomycin MBC/MIC ratios consistent with drug tol-
erance. Thus, the results of this study, along with previous
reports, suggest that daptomycin may be more appropriate
than vancomycin for the treatment of infections that require a
bactericidal agent. These results also encourage the wider use
of MBC testing when vancomycin is selected for therapy for
serious MRSA infections.
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